SMC1A: A Potential Drug Target for Neurological and Psychiatric Disorders

Target Name: SMC1A

NCBI ID: G8243

SMC1A

SMC1A: A Potential Drug Target for Neurological and Psychiatric Disorders

SMC1A, short for small subunitary cell component 1A, is a protein that is expressed in the brain and is involved in the development and maintenance of neural stem cells. It is a key regulator of stem cell survival and proliferation, and has been identified as a potential drug target for various neurological and psychiatric disorders.

SMC1A was first identified in 2004 using RNA interference techniques, and has since been shown to play a crucial role in the development and maintenance of neural stem cells in the brain. It is a protein that is expressed in the brain and is involved in the development and maintenance of neural stem cells. SMC1A is a key regulator of stem cell survival and proliferation, and has been identified as a potential drug target for various neurological and psychiatric disorders.

One of the key functions of SMC1A is its role in the development and maintenance of neural stem cells. These cells are responsible for the formation and maintenance of the nervous system, and are a crucial part of the development and maintenance of a healthy brain. SMC1A is involved in the production of these stem cells, and is also involved in the regulation of their survival and proliferation.

Another function of SMC1A is its role in the regulation of cell division. SMC1A has been shown to play a role in the regulation of cell division in the brain, and is involved in the production of neurons. This is important for the development and maintenance of the nervous system, and is a crucial part of the treatment of neurological and psychiatric disorders.

In addition to its role in the development and maintenance of neural stem cells, SMC1A is also involved in the regulation of stem cell plasticity. This is the ability of stem cells to change and adapt to different forms, and is important for the development and maintenance of the nervous system. SMC1A is involved in the regulation of stem cell plasticity, and is a potential drug target for the treatment of psychiatric disorders.

SMC1A is also involved in the regulation of cell adhesion. This is the ability of cells to stick together and form tissues, and is important for the development and maintenance of the nervous system. SMC1A is involved in the regulation of cell adhesion, and is a potential drug target for the treatment of psychiatric disorders.

In conclusion, SMC1A is a protein that is expressed in the brain and is involved in the development and maintenance of neural stem cells. It is a key regulator of stem cell survival and proliferation, and has been identified as a potential drug target for various neurological and psychiatric disorders. Further research is needed to fully understand the role of SMC1A in the development and maintenance of neural stem cells, and to identify potential drug targets.

Protein Name: Structural Maintenance Of Chromosomes 1A

Functions: Involved in chromosome cohesion during cell cycle and in DNA repair. Central component of cohesin complex. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. Involved in DNA repair via its interaction with BRCA1 and its related phosphorylation by ATM, or via its phosphorylation by ATR. Works as a downstream effector both in the ATM/NBS1 branch and in the ATR/MSH2 branch of S-phase checkpoint

The "SMC1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMC1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets